Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Conditions
Interventions
Inhaled treprostinil solution
Placebo solution
Locations
76
United States
The University of Alabama at Birmingham
Birmingham, Alabama, United States
Banner University Medical Center
Phoenix, Arizona, United States
University of Arizona Clinical and Translational Science (CATS) Research Center
Tucson, Arizona, United States
Loma Linda University Medical Center
Loma Linda, California, United States
University of Southern California
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Start Date
May 8, 2018
Primary Completion Date
October 13, 2022
Completion Date
October 13, 2022
Last Updated
November 24, 2023
NCT07190209
NCT05746039
NCT07509606
NCT03854071
NCT07073820
NCT07477600
Lead Sponsor
United Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions